Bipolar Androgen-based Therapy for Prostate Cancer (BAT)
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and clinical effects of alternating
androgen deprivation therapy with testosterone therapy in men with recurrent prostate cancer
as first line hormonal therapy, to assess the effect of alternating therapy on quality of
life and metabolic changes associated with androgen-deprivation therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins